Search Results - "Gazawi, N."

  • Showing 1 - 3 results of 3
Refine Results
  1. 1
    1853P Real-world evidence of quality of life effects (QoL) of the antiemetic NEPA: Final data in patients receiving oxaliplatin-based chemotherapy within the AkyPRO-trial

    1853P Real-world evidence of quality of life effects (QoL) of the antiemetic NEPA: Final data in patients receiving oxaliplatin-based chemotherapy within the AkyPRO-trial by Karthaus, M., Welslau, M.K., Gazawi, N., Neise, M., Rauh, J., Whitlock, B., Boheme, V., Grunewald, M., Schilling, J.

    Published in Annals of oncology (01-09-2020)
    Get full text
    Journal Article
    Save to List
    Saved in:
  2. 2
    Patient Reported Outcome (PRO) in Patients Receiving High and Moderate Emetogenic Chemotherapy (Ctx) - Results of a German Prospective Non-Interventional Study with Netupitant/Palonosetron Fixed Dose Combination (NEPA)

    Patient Reported Outcome (PRO) in Patients Receiving High and Moderate Emetogenic Chemotherapy (Ctx) - Results of a German Prospective Non-Interventional Study with Netupitant/Palonosetron Fixed Dose Combination (NEPA) by Karthaus, Meinolf, Klare, P, Gazawi, N, Zahn, MO, Reimann, B, Busch, S, Schilling, Joerg

    Published in Blood (29-11-2018)
    “…Introduction:NEPA is a fixed dose combination of the NK1-receptor antagonist (RA) netupitant and 5-HT3-RA palonosetron approved for prevention of…”
    Get full text
    Journal Article
    Save to List
    Saved in:
  3. 3
    Adjuvant treatment strategy and results in small breast cancer tumors (pT1) with HER2 overexpression

    Adjuvant treatment strategy and results in small breast cancer tumors (pT1) with HER2 overexpression by Hinke, A., Dall, P., Lenzen, G., Schumacher, C., Rezek, D., Gazawi, N., Ammon, A., Foerster, F. G., Beldermann, F., Cirrincione, U., Wilke, J.

    Published in Journal of clinical oncology (20-05-2011)
    “…Abstract only…”
    Get full text
    Journal Article
    Save to List
    Saved in:

Search Tools: